arrow
M

Melissa Burgess

pennsylvania commonwealth system of higher education (pcshe)
H指数:22
被引数:5,437

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

Nguyen, M.K.; Jelinek, M.; Singh, A.; Isett, B.; Myers, E.S.; Mullett, S.J.; Eisele, Y.; Beumer, J.; Parise, R.; Urban, J.; et al. 关于ivosidenib联合nivolumab治疗携带IDH1突变的晚期实体瘤的临床与转化研究。medRxiv 2025. [Google Scholar] [CrossRef]

2025-11-010
PRE
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

pembrolizumab,放射治疗和手术与放射治疗和手术治疗肢体III期软组织肉瘤的安全性和有效性 (SU2C-SARC032): 一项开放标签,随机临床试验

LANCET
IF88.5
2024-11-010
PRE
Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma
2024-04-050
PRE
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
2024-03-063
PRE
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
2023-09-0739
OA
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
2023-03-09106
PRE
SAFETY AND PRELIMINARY EFFICACY OF INTRATUMORAL CAVROTOLIMOD (AST-008), A SPHERICAL NUCLEIC ACID TLR9 AGONIST, IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
2020-12-1010
PREAI